Valeant Pharmaceuticals International Inc., of Laval, Quebec, said it priced its previously announced offering of $1.25 billion aggregate principal amount of 6.5 percent senior secured notes due 2022 and $2 billion aggregate principal amount of 7 percent senior secured notes due 2024.